3SRP

Structure of Rivax: A Human Ricin Vaccine

「3BJG」から置き換えられました

3SRP の概要

• エントリーDOI: 10.2210/pdb3srp/pdb
• 関連するPDBエントリー: 3BJG 3LC9 3MK9
• 分子名称: Ricin A chain, SULFATE ION (3 entities in total)
• 機能のキーワード: immunogen, ribosome inactivating protein, hydrolase
• 由来する生物種: Ricinus communis (Castor bean)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 30200.05

構造登録者

Legler, P.M.,Millard, C.B. (登録日: 2011-07-07, 公開日: 2011-08-03, 最終更新日: 2023-09-13)

主引用文献

Legler, P.M.,Brey, R.N.,Smallshaw, J.E.,Vitetta, E.S.,Millard, C.B.
Structure of RiVax: a recombinant ricin vaccine.
Acta Crystallogr.,Sect.D, 67:826-830, 2011

PubMed Abstract: RiVax is a recombinant protein that is currently under clinical development as part of a human vaccine to protect against ricin poisoning. RiVax includes ricin A-chain (RTA) residues 1-267 with two intentional amino-acid substitutions, V76M and Y80A, aimed at reducing toxicity. Here, the crystal structure of RiVax was solved to 2.1 Å resolution and it was shown that it is superposable with that of the ricin toxin A-chain from Ricinus communis with a root-mean-square deviation of 0.6 Å over 258 C(α) atoms. The RiVax structure is also compared with the recently determined structure of another potential ricin-vaccine immunogen, RTA 1-33/44-198 R48C/T77C. Finally, the locations and solvent-exposure of two toxin-neutralizing B-cell epitopes were examined and it was found that these epitopes are within or near regions predicted to be involved in catalysis. The results demonstrate the composition of the RiVax clinical material and will guide ongoing protein-engineering strategies to develop improved immunogens.

PubMed: 21904036
DOI: 10.1107/S0907444911026771

実験手法

X-RAY DIFFRACTION (2.14 Å)